A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004/NCI 8503).
about
Signaling Pathways in Thyroid Cancer and Their Therapeutic ImplicationsNotch signaling deregulation in multiple myeloma: A rational molecular targetA phase II study of paclitaxel for the treatment of ovarian stromal tumors: An NRG Oncology/ Gynecologic Oncology Group Study.A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients.Notch signaling in serous ovarian cancer.A phase II study of the gamma secretase inhibitor RO4929097 in patients with previously treated metastatic pancreatic adenocarcinomaA multicenter phase 1 study of γ -secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors.Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches.Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical updatePotential Therapeutic Targets in Uterine Sarcomas.Identification of thiostrepton as a novel therapeutic agent that targets human colon cancer stem cells.Emerging therapeutic targets in metastatic progression: A focus on breast cancer.Targeting notch signaling pathway in cancer: clinical development advances and challengesTherapeutic modulation of Notch signalling--are we there yet?The angiogenic asset of soft tissue sarcomas: a new tool to discover new therapeutic targets.Notch functions in developmental and tumour angiogenesis by diverse mechanisms.Notching on Cancer's Door: Notch Signaling in Brain Tumors.Breast cancer stem cells: are we ready to go from bench to bedside?The role of Notch signaling in the mammalian ovary.Antiangiogenesis and vascular disrupting agents in cancer: circumventing resistance and augmenting their therapeutic utility.Molecular and Clinical Effects of Notch Inhibition in Glioma Patients: A Phase 0/I Trial.Inhibition of γ-secretase activity synergistically enhances tumour necrosis factor-related apoptosis-inducing ligand induced apoptosis in T-cell acute lymphoblastic leukemia cells via upregulation of death receptor 5Targeting Notch Signaling and Autophagy Increases Cytotoxicity in Glioblastoma Neurospheres.Phase I study of RO4929097 with bevacizumab in patients with recurrent malignant glioma.Notch Signaling in Development, Tissue Homeostasis, and Disease.Novel Small Molecule Inhibitors of Cancer Stem Cell Signaling Pathways.Perspectives on the discovery of NOTCH2-specific inhibitors.Inhibition of Farnesyltransferase Potentiates NOTCH-Targeted Therapy against Glioblastoma Stem Cells.[(3) H]-L685,458 binding sites are abundant in multiple peripheral organs in rats: implications for safety assessment of putative γ-secretase targeting drugs.Activation of multiple angiogenic signaling pathways in hemangiopericytoma.Targeting Notch signalling pathway of cancer stem cells.Exploring major signaling cascades in melanomagenesis: a rationale route for targetted skin cancer therapy
P2860
Q26764899-C21D374B-E3B9-4C3D-8E5D-41DF05FB4A4EQ26797283-FC242CC6-232B-4582-BB72-6B4CD4B88C0FQ30355928-3DA43603-4A7E-4972-B38F-D11601A06F70Q33415009-46FD2446-05B4-4A7D-B9BA-823884888215Q34491211-F5946987-DADC-4330-807C-8D6BF5FAE16AQ34938155-672B9176-5AB0-43EE-9BFA-F43F6BAD9B8CQ34978436-AA71FF66-9A47-4669-9481-30AC2C0E9E50Q35205410-7A954EB7-D290-448A-A919-A685E4F1A56DQ35904534-92224303-5F45-4E0D-9C11-02D402C61920Q36245677-931B63FD-FB78-4D43-8C96-1000486084A3Q36293810-AFD4BDF3-A11D-4688-B2DF-72424AB4D3E7Q36854062-EA772281-8730-4F14-A7B0-4EFB6163A09FQ37696748-3377D04C-6988-4F3F-8A25-41A508A3C865Q38208211-1DB10999-03F1-4E4B-9384-AE88442F6CFDQ38252537-092775AB-2C66-4A26-965F-C0CE74FC0643Q38268444-1A72F84A-D5FB-4609-909F-92AA27CDC836Q38324552-BD6A2F20-9878-4548-8059-A5D513F795D6Q38696803-D818F6D9-0E7B-46D2-8D4B-BD92801CA6A3Q38747422-49EC49C8-82E9-4AC3-91A1-1D42FCBF5BF6Q38757723-E44DA6D0-0A03-4E26-9081-9E01E5E27A93Q39786861-364E6F15-DBB1-46BE-A3A5-6CC0ED5161A9Q41195048-6165ED6F-51BF-4044-A107-29E8E16C2CF9Q41916292-583A4870-1CA2-48E4-AC70-F5B529A27698Q45933412-41C4F467-8FD9-4292-B5CA-3906B8AB5B5BQ46795621-7AA6713B-E7B1-4FEB-A6D7-AB296F7223B7Q47827202-C7A506B9-0F41-4664-A02E-28234881A127Q48113221-EECDAF03-B81C-49ED-BAE4-232FBCD4263AQ48583242-316C4610-6975-4DD2-85F5-AB69296CCA0AQ48767057-F7F85A5B-18E3-41DF-B66B-54ECC9C4B0CCQ48854018-BD39C2A7-D468-4E1F-9115-C4358FE85DDAQ52571053-1C903F51-9472-4011-B4FE-3B645B7951B0Q57044361-1BA4D0F3-AFA8-4963-BA5C-183306CC715A
P2860
A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004/NCI 8503).
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
A phase I study of the combina ...... id tumours (PJC-004/NCI 8503).
@en
A phase I study of the combina ...... ts with advanced solid tumours
@nl
type
label
A phase I study of the combina ...... id tumours (PJC-004/NCI 8503).
@en
A phase I study of the combina ...... ts with advanced solid tumours
@nl
prefLabel
A phase I study of the combina ...... id tumours (PJC-004/NCI 8503).
@en
A phase I study of the combina ...... ts with advanced solid tumours
@nl
P2093
P2860
P50
P356
P1476
A phase I study of the combina ...... lid tumours (PJC-004/NCI 8503)
@en
P2093
A McGarrity
A R A Razak
P2860
P2888
P304
P356
10.1038/BJC.2013.380
P407
P577
2013-07-18T00:00:00Z